Har­bour Bio­Med nets $75M in Se­ries B+ as first glob­al tri­al gets un­der­way

Near­ly two years af­ter draw­ing an $85 mil­lion Se­ries B, Shang­hai-based Har­bour Bio­Med has an­nounced a new large fund­ing round.

In what they’re billing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.